Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of [18F]LY4214835 in Healthy Volunteers and Cancer Patients
NCT07258836Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]LY4214835 in cancer, sponsored by Eli Lilly and Company. Primary endpoints: Incidence of Adverse Events at Day 3 and Radiation Absorbed Dose Estimates in Body Organs to Obtain Whole-body Effective Dose at Day 3. Started Dec 2025; status: recruiting.
02
Drugs
[18F]LY4214835
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07258836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258836.